Cardiovascular Medicines · LP-049
Captopril Tablets
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-049Cardiovascular Medicines
- Generic identity
- CaptoprilTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-049
- Generic identity
- Captopril
- Presentation
- Tablet
- Catalogue strength
- 12.5 mg; 25 mg; 50 mg
- Catalogue pack
- Blister 10 x 10 tablets
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: Captopril.
- Dosage form: tablet.
- Catalogue strength / concentration: 12.5 mg; 25 mg; 50 mg.
- Catalogue pack: Blister 10 x 10 tablets.
- Catalogue category: Cardiovascular Medicines.
Layer 02 · Unresolved product-specific fields
- Exact finished-product composition, excipients and manufacturing specification.
- Tablet score/divisibility, excipients and any administration conditions tied to the exact formulation.
- Approved indication, patient eligibility, dose/administration and contraindication wording for the exact product/jurisdiction.
- Storage conditions, shelf life, registration/market status, manufacturing route and current supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 12.5 mg | Tablet | — | Catalogue lists blister 10 x 10 tablets; strength-specific controlled SKU evidence not supplied | The strength and common blister description are catalogue facts; do not infer score, dose, interchangeability or controlled SKU status. |
| B | 25 mg | Tablet | — | Catalogue lists blister 10 x 10 tablets; strength-specific controlled SKU evidence not supplied | The strength and common blister description are catalogue facts; do not infer score, dose, interchangeability or controlled SKU status. |
| C | 50 mg | Tablet | — | Catalogue lists blister 10 x 10 tablets; strength-specific controlled SKU evidence not supplied | The strength and common blister description are catalogue facts; do not infer score, dose, interchangeability or controlled SKU status. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Captopril is an angiotensin-converting enzyme inhibitor used in selected cardiovascular and renal clinical settings. It acts on the renin–angiotensin system and can affect blood pressure, kidney function and potassium. Clinical decisions therefore require more than a tablet-strength comparison. This educational ingredient profile does not establish a Luang Pharma approved indication, confirm product equivalence or replace the monitoring needed when a prescriber initiates or changes treatment.
Clinical context and therapeutic role
A professional considers the diagnosis, blood pressure, renal function, potassium and concomitant medicines before selection. The place of an ACE inhibitor in hypertension, heart failure or another condition depends on current guidance and patient factors. A history of angioedema is especially important. Pregnancy or pregnancy planning requires prompt discussion because this class can harm the fetus. Intercurrent vomiting, diarrhoea or dehydration may require review of the existing treatment plan.
Selected safety context
Angioedema involving the lips, tongue or airway can be life-threatening and requires emergency care. Other important risks include high potassium, kidney impairment and excessive blood-pressure reduction. Cough, altered taste or rash may occur. Potassium supplements, potassium-containing salt substitutes, some diuretics, lithium and NSAIDs warrant review. Pregnancy is a major safety concern. A clinician may need blood tests; weakness, fainting, reduced urine or signs of serious infection should be assessed.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue describes a tablet presentation. The exact salt, coating, score line and release characteristics need confirmation from the authorized product information. A milligram strength identifies ingredient quantity; it does not establish whether a tablet may be split, crushed or exchanged for another formulation.
Keep the product in its labeled packaging so the batch, expiry and instructions remain identifiable. Follow the actual label for storage conditions and disposal. Do not use a damaged or unidentified tablet, and keep all medicines securely out of children’s reach.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A qualified clinician should review the cardiovascular indication, blood pressure or pulse where relevant, organ function and interacting medicines. Monitoring and treatment changes must be linked to the individual care plan and the authorized product information.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specification and quantitative composition for each exact presentation.
Approved/controlled label or leaflet for the intended jurisdiction.
Strength/form-to-pack SKU matrix and controlled packaging artwork where more than one variant is listed.
Registration/market-status and manufacturing-site evidence for the exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07c checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| MedlinePlus: CaptoprilArchived source classification: NLM-hosted medicine monograph | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-049.
Professional enquiries
Request product-specific evidence for LP-049.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.